US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by Rezolute, Inc.

< Previous 1 2 Next >
News headline image
Rezolute Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Business Update
From Rezolute, Inc.
Via GlobeNewswire
Tickers RZLT
News headline image
Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism
From Rezolute, Inc.
Via GlobeNewswire
Tickers RZLT
News headline image
Rezolute to Participate in Upcoming Investor Conferences
From Rezolute, Inc.
Via GlobeNewswire
Tickers RZLT
News headline image
Rezolute to Participate in the BTIG Virtual Biotechnology Conference
From Rezolute, Inc.
Via GlobeNewswire
Tickers RZLT
News headline image
Rezolute Highlights Results Presented from Natural History Outcomes Studies and its Ersodetug Clinical Program in Hyperinsulinism at Annual Meeting of the Endocrine Society
From Rezolute, Inc.
Via GlobeNewswire
Tickers RZLT
News headline image
Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society
From Rezolute, Inc.
Via GlobeNewswire
Tickers RZLT
News headline image
Rezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism
From Rezolute, Inc.
Via GlobeNewswire
Tickers RZLT
News headline image
Rezolute Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update
From Rezolute, Inc.
Via GlobeNewswire
Tickers RZLT
News headline image
Rezolute to Participate in Upcoming Investor Conferences
From Rezolute, Inc.
Via GlobeNewswire
Tickers RZLT
News headline image
Rezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism at the Pediatric Endocrine Society Annual Meeting
From Rezolute, Inc.
Via GlobeNewswire
Tickers RZLT
News headline image
Rezolute to Present Results from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism at the Pediatric Endocrine Society (PES) Annual Meeting
From Rezolute, Inc.
Via GlobeNewswire
Tickers RZLT
News headline image
Rezolute Provides Update on its Congenital Hyperinsulinism Program Following FDA Meeting
From Rezolute, Inc.
Via GlobeNewswire
Tickers RZLT
News headline image
Rezolute to Participate in the Citizens Life Sciences Conference
From Rezolute, Inc.
Via GlobeNewswire
Tickers RZLT
News headline image
Rezolute Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update
From Rezolute, Inc.
Via GlobeNewswire
Tickers RZLT
News headline image
Rezolute to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
From Rezolute, Inc.
Via GlobeNewswire
Tickers RZLT
News headline image
Rezolute Provides Insights from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism and Shares Findings from its Expanded Access Program in Tumor Hyperinsulinism
From Rezolute, Inc.
Via GlobeNewswire
Tickers RZLT
News headline image
Rezolute Announces Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism
From Rezolute, Inc.
Via GlobeNewswire
Tickers RZLT
News headline image
Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Rezolute, Inc.
Via GlobeNewswire
Tickers RZLT
News headline image
Rezolute Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update
From Rezolute, Inc.
Via GlobeNewswire
Tickers RZLT
News headline image
Rezolute to Host Virtual Investor Event on Ersodetug Development Program
From Rezolute, Inc.
Via GlobeNewswire
Tickers RZLT
News headline image
Rezolute to Participate in Upcoming Investor Conferences
From Rezolute, Inc.
Via GlobeNewswire
Tickers RZLT
News headline image
Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Rezolute, Inc.
Via GlobeNewswire
Tickers RZLT
News headline image
Rezolute Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business Update
From Rezolute, Inc.
Via GlobeNewswire
Tickers RZLT
News headline image
Rezolute Announces Alignment with FDA on Streamlined Design for Ongoing Phase 3 Trial of Ersodetug in Tumor Hyperinsulinism
From Rezolute, Inc.
Via GlobeNewswire
Tickers RZLT
News headline image
Rezolute to Participate in Upcoming Investor Conferences
From Rezolute, Inc.
Via GlobeNewswire
Tickers RZLT
News headline image
Rezolute Appoints Seasoned Commercial Executive Sunil Karnawat as Chief Commercial Officer
From Rezolute, Inc.
Via GlobeNewswire
Tickers RZLT
News headline image
Rezolute to Participate in the BTIG Virtual Biotechnology Conference
From Rezolute, Inc.
Via GlobeNewswire
Tickers RZLT
News headline image
Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (ENDO 2025)
From Rezolute, Inc.
Via GlobeNewswire
Tickers RZLT
News headline image
Rezolute Announces Completion of Enrollment in the Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism
From Rezolute, Inc.
Via GlobeNewswire
Tickers RZLT
News headline image
Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update
From Rezolute, Inc.
Via GlobeNewswire
Tickers RZLT
< Previous 1 2 Next >